As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
Desmopressin Acetate Injection is primarily used to treat central diabetes insipidus, haemophilia A, and von Willebrand disease
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
The approval introduces a needle-free alternative to injectable GLP-1 therapies
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
Subscribe To Our Newsletter & Stay Updated
